Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (IT:1BMY)
:1BMY
1BMY Stock Chart & Stats
€46.16
€0.63(1.16%)
At close: 4:00 PM EST
€46.16
€0.63(1.16%)
Day’s Range― - ―
52-Week Range€33.00 - €59.13
Previous CloseN/A
Volume0.00
Average Volume (3M)227.00
Market Cap
$94.03B
Enterprise Value€126.55B
Total Cash (Recent Filing)$16.50B
Total Debt (Recent Filing)$51.04B
Price to Earnings (P/E)17.2
Beta0.31
Next Earnings
Feb 05, 2026EPS Estimate
1.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.39
Shares Outstanding2,035,753,000
10 Day Avg. Volume98
30 Day Avg. Volume227
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)7.02
Price to Sales (P/S)2.37
P/FCF Ratio8.22
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue2.63
Enterprise Value/Gross Profit4.00
Enterprise Value/Ebitda8.49
Forecast
1Y Price Target
$45.89Price Target Upside-0.58% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Catalyst-Rich PeriodBMY is approaching a catalyst-rich period with multiple scenarios that could position the company for a return to growth.
Pipeline CatalystsA cadence of material pipeline catalysts, including FXIa, LPA1, and Sotatercept, is seen in 2026.
R&D Pipeline GrowthBMY's R&D pipeline is expected to deliver key de-risking catalysts, offering a favorable risk/reward scenario.
Bears Say
ADEPT-2 Trial DelayADEPT-2 delay rounds out a more challenging year in the clinic for Bristol shares.
Patent ExpirationsImpending product patent expirations are likely to drive a discount in BMY's share price.
Revenue ForecastHigh revenue decline is forecasted due to losses in the heme-onc portfolio and other areas.
Bristol-Myers Squibb News
1BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was €33.00 and its highest was €59.13 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is $94.03B.
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Feb 05, 2026 which is in 49 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Oct 30, 2025. The company reported €1.388 earnings per share for the quarter, beating the consensus estimate of €1.293 by €0.095.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Overvalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb does not currently pay dividends.
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is 1.4.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,035,753,000 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of €1.388 in its last earnings report, beating expectations of €1.293. Following the earnings report the stock price went up 5.917%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Currently, no hedge funds are holding shares in IT:1BMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bristol-Myers Squibb Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$45.89 (-0.58% Downside)
$45.89 (-0.58% Downside)
Blogger Sentiment
Bullish
IT:1BMY Sentiment 87%
Sector Average 68%
Sector Average 68%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.89%
12-Months-Change
Fundamentals
Return on Equity
33.84%
Trailing 12-Months
Asset Growth
3.44%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
1BMY Company Deck
1BMY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with strong growth in the portfolio, increased revenue guidance, and successful business development activities. However, there remain challenges with the adoption of new products like Cobenfy and the uncertainty surrounding IRA negotiations.View all IT:1BMY earnings summaries1BMY Revenue Breakdown
46.71% Growth Portfolio
53.29% Legacy Portfolio
1BMY Stock 12 Month Forecast
Average Price Target
€45.89
▼(-0.58% Downside)
Technical Analysis
Options Prices
Currently, No data available
---